{"id":5484,"date":"2024-02-07T01:13:42","date_gmt":"2024-02-07T01:13:42","guid":{"rendered":"https:\/\/economicherald.net\/?p=5484"},"modified":"2024-02-07T01:13:42","modified_gmt":"2024-02-07T01:13:42","slug":"asx-health-stocks-truscreen-to-start-cervical-cancer-screening-women-in-mexico-after-approval","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=5484","title":{"rendered":"ASX Health Stocks: Truscreen to start cervical cancer screening women in Mexico after approval"},"content":{"rendered":"<p>Truscreen granted approval in Mexico<br \/>\nThe company can now gain direct access to Mexico\u2019s public health sector<br \/>\nNeurotech reports results from its Phase I\/II cannabis clinical trial<\/p>\n<p>\u00a0<\/p>\n<h2>TruScreen gets approval in Mexico<\/h2>\n<p>Medical device company, <strong><a href=\"https:\/\/stockhead.com.au\/company\/truscreen-group-tru\/\">TruScreen Group (ASX:TRU)<\/a><\/strong>, has received a <strong>Cofepris approval<\/strong> in Mexico, giving it access to the country\u2019s public health sector.<\/p>\n<p>The Cofepris is Mexico\u2019s regulatory body equivalent to the US FDA.<\/p>\n<p>The approval allows TruScreen to expand its <strong>cervical cancer screening,<\/strong> currently, in the private health clinics, to the wider public health sector.<\/p>\n<p>A 2020 census identified that only 2.3% of the Mexican population have private healthcare, while 70.9% of the population accessed the public health system.<\/p>\n<p>Mexico meanwhile has an addressable market of 65 million women. Of that, 9,400 women are diagnosed annually with cervical cancer with a mortality rate of 46% \u2013 or 4,300 deaths.<\/p>\n<p>Cervical cancer has now become the second most prevalent cancer amongst women in Mexico.<\/p>\n<p>\u201cThe Cofepris approval highlights the accelerating acceptance of the TruScreen technology globally,\u201d said <strong>TruScreen\u2019s CEO, Dr Beata Edling.<\/strong><\/p>\n<p>\u201cI am delighted that women in Mexico will have access to faster, more efficient, and reliable cervical cancer screening with TruScreen.\u201d<\/p>\n<p>TruScreen\u2019s cervical screening technology, <strong>TruScreen Ultra,<\/strong> could detect abnormalities in the cervical tissue in real-time, via measurements of the low level of optical and electrical stimuli.<\/p>\n<p>The device is CE Marked\/EC certified, ISO 13485 compliant, and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and now COFEPRIS (Mexico).<\/p>\n<p>It also has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries.<\/p>\n<p>\u00a0<\/p>\n<h2>Neurotech\u2019s Phase 1\/2 results<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/neurotech-nti\/\">Neurotech (ASX:NTI)<\/a><\/strong> has provided an update on the progress of the 11 <strong>autism spectrum disorder (ASD)<\/strong> patients who were part of the company\u2019s world-first <strong>Phase 1\/2 clinical trial<\/strong>.<\/p>\n<p>The trial originally examined the daily use of Neurotech\u2019s proprietary broad spectrum <strong>cannabinoid drug therapy, NTI164<\/strong>, out to 52 weeks of treatments.<\/p>\n<p>All patients have now crossed 90 weeks of daily oral therapy with NTI164.<\/p>\n<p>Results show that NTI164 continues to exhibit a safety and tolerability profile, with all patients showing stable blood chemistries and normal liver and kidney function over 90 weeks.<\/p>\n<p>Although no further quantitative efficacy analysis has been collected since week 52, caregiver and clinician reports remain positive with symptomatic improvement maintained at the 90-week mark.<\/p>\n<p>The trial was the longest ever study in ASD, examining the safety of a broad spectrum cannabinoid drug treatment.<\/p>\n<p>Data from this trial will support future regulatory interactions and filings for NTI164.<\/p>\n<p>Following the conclusion of this study, Neurotech says it\u2019s now on track to report the next phase \u2013 Phase 2\/3 ASD clinical trial data \u2013 in late Q1 to early Q2 this year.<\/p>\n<p>\u00a0<\/p>\n<h2>Share prices today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span>\u00a0<\/p>\n<p><em>At Stockhead we tell it like it is. While Neurotech is a Stockhead advertiser, it did not sponsor this article.<\/em><\/p>\n<p><span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-truscreen-to-start-cervical-cancer-screening-women-in-mexico-after-approval\/\">ASX Health Stocks: Truscreen to start cervical cancer screening women in Mexico after approval<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Truscreen granted approval in Mexico The company can now gain direct access to Mexico\u2019s public health sector Neurotech reports results from its Phase I\/II cannabis <a href=\"https:\/\/economicherald.net\/?p=5484\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":5485,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-5484","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Truscreen to start cervical cancer screening women in Mexico after approval - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=5484\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Truscreen to start cervical cancer screening women in Mexico after approval - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Truscreen granted approval in Mexico The company can now gain direct access to Mexico\u2019s public health sector Neurotech reports results from its Phase I\/II cannabis [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=5484\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-07T01:13:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Truscreen-granted-approval-in-Mexico.-Picture-Getty-mDJPXJ.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5484#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5484\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Truscreen to start cervical cancer screening women in Mexico after approval\",\"datePublished\":\"2024-02-07T01:13:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5484\"},\"wordCount\":512,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5484#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Truscreen-granted-approval-in-Mexico.-Picture-Getty-mDJPXJ.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=5484#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5484\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=5484\",\"name\":\"ASX Health Stocks: Truscreen to start cervical cancer screening women in Mexico after approval - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5484#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5484#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Truscreen-granted-approval-in-Mexico.-Picture-Getty-mDJPXJ.jpeg\",\"datePublished\":\"2024-02-07T01:13:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5484#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=5484\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5484#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Truscreen-granted-approval-in-Mexico.-Picture-Getty-mDJPXJ.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Truscreen-granted-approval-in-Mexico.-Picture-Getty-mDJPXJ.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5484#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Truscreen to start cervical cancer screening women in Mexico after approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Truscreen to start cervical cancer screening women in Mexico after approval - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=5484","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Truscreen to start cervical cancer screening women in Mexico after approval - Economic Herald","og_description":"Truscreen granted approval in Mexico The company can now gain direct access to Mexico\u2019s public health sector Neurotech reports results from its Phase I\/II cannabis [more...]","og_url":"https:\/\/economicherald.net\/?p=5484","og_site_name":"Economic Herald","article_published_time":"2024-02-07T01:13:42+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Truscreen-granted-approval-in-Mexico.-Picture-Getty-mDJPXJ.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=5484#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=5484"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Truscreen to start cervical cancer screening women in Mexico after approval","datePublished":"2024-02-07T01:13:42+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=5484"},"wordCount":512,"commentCount":0,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=5484#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Truscreen-granted-approval-in-Mexico.-Picture-Getty-mDJPXJ.jpeg","articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/economicherald.net\/?p=5484#respond"]}]},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=5484","url":"https:\/\/economicherald.net\/?p=5484","name":"ASX Health Stocks: Truscreen to start cervical cancer screening women in Mexico after approval - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=5484#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=5484#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Truscreen-granted-approval-in-Mexico.-Picture-Getty-mDJPXJ.jpeg","datePublished":"2024-02-07T01:13:42+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=5484#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=5484"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=5484#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Truscreen-granted-approval-in-Mexico.-Picture-Getty-mDJPXJ.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Truscreen-granted-approval-in-Mexico.-Picture-Getty-mDJPXJ.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=5484#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Truscreen to start cervical cancer screening women in Mexico after approval"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/5484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5484"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/5484\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/5485"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}